REFRACTORY PLASMA CELL MYELOMA
Clinical trials for REFRACTORY PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat myeloma in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs—venetoclax and tocilizumab—in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. The trial includes both African American and non-African Am…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 17, 2026 10:40 UTC
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 10:37 UTC
-
Immune cells trained to hunt myeloma in early trial
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T-cells) that are trained to recognize and attack cancer cells carrying a protein called MUC1. The mai…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
Virus-Enhanced cocktail takes on tough myeloma
Disease control OngoingThis early-phase study tests a combination of standard chemotherapy (bortezomib, dexamethasone), an immunotherapy (pembrolizumab), and a lab-modified virus (pelareorep) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if …
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control OngoingThis study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in about 5 adults with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if the combination can shrink or control the cancer. This is a diseas…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug combo shows promise for Tough-to-Treat myeloma
Disease control OngoingThis study tests a two-step treatment plan for people with multiple myeloma that has come back or stopped responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:56 UTC